A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
Emtage
L A
LA
West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham, UK.
Trethowan
C
C
Kelly
K
K
Arkell
D
D
Wallace
D M
DM
Hughes
M
M
Hay
A
A
Blacklock
R
R
Jones
M
M
Rouse
A
A
D000368:Aged; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000627:therapeutic use*; D017273:Goserelin; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D006113:United Kingdom
D003692:Delayed-Action Preparations; D017273:Goserelin; D004054:Diethylstilbestrol; D002064:Buserelin